{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&answer.answeringMember.label=Biography+information+for+George+Freeman", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&answer.answeringMember.label=Biography+information+for+George+Freeman", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&_metadata=all&answer.answeringMember.label=Biography+information+for+George+Freeman", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&answer.answeringMember.label=Biography+information+for+George+Freeman", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&answer.answeringMember.label=Biography+information+for+George+Freeman", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptId=17&answer.dateOfAnswer=2014-10-21&max-date=2019-05-14&answer.answeringMember.label=Biography+information+for+George+Freeman", "items" : [{"_about" : "http://data.parliament.uk/resources/93839", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93839/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.<br> <br> Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:<\/p><p> <\/p><table><tbody><tr><td><p>Appraisal Number<\/p><\/td><td><p>Year<\/p><\/td><td><p>Technology<\/p><\/td><td><p>Condition<\/p><\/td><td><p>Categorisation<\/p><\/td><\/tr><tr><td><p>TA59<\/p><\/td><td><p>2003<\/p><\/td><td><p>Electroconvulsive therapy<\/p><\/td><td><p>Catatonia/ prolonged or severe manic episode<\/p><\/td><td><p>Optimised<sup>1<\/sup><\/p><\/td><\/tr><tr><td><p>TA098<\/p><\/td><td><p>2006<\/p><\/td><td><p>Atomoxetine<\/p><\/td><td><p>Attention deficit hyperactivity disorder (ADHD)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA098<\/p><\/td><td><p>2006<\/p><\/td><td><p>Dexamfetamine<\/p><\/td><td><p>Attention deficit hyperactivity disorder (ADHD)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA098<\/p><\/td><td><p>2006<\/p><\/td><td><p>Methylphenidate<\/p><\/td><td><p>Attention deficit hyperactivity disorder (ADHD)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA213<\/p><\/td><td><p>2011<\/p><\/td><td><p>Aripiprazole<\/p><\/td><td><p>Schizophrenia in people aged 15-17 years<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA217<\/p><\/td><td><p>2011<\/p><\/td><td><p>Donepezil<\/p><\/td><td><p>Alzheimer's disease (mild to moderate)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA217<\/p><\/td><td><p>2011<\/p><\/td><td><p>Galantamine<\/p><\/td><td><p>Alzheimer's disease (mild to moderate)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA217<\/p><\/td><td><p>2011<\/p><\/td><td><p>Rivastigmine<\/p><\/td><td><p>Alzheimer's disease (mild to moderate)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA217<\/p><\/td><td><p>2011<\/p><\/td><td><p>Memantine<\/p><\/td><td><p>Alzheimer's disease (moderate)<\/p><\/td><td><p>Optimised<\/p><\/td><\/tr><tr><td><p>TA217<\/p><\/td><td><p>2011<\/p><\/td><td><p>Memantine<\/p><\/td><td><p>Alzheimer's disease (severe)<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><tr><td><p>TA292<\/p><\/td><td><p>2013<\/p><\/td><td><p>Aripiprazole<\/p><\/td><td><p>Moderate to severe manic episodes in adolescents with bipolar disorder<\/p><\/td><td><p>Recommended<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p><em>Source<\/em>: National Institute for Health and Care Excellence<\/p><p> <\/p><p> <\/p><p> <\/p><p><sup>1 <\/sup>The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Details of all NICE\u2019s guidance on mental health and behavioural conditions can be found at:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions\" target=\"_blank\">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions<\/a><\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-21T15:12:00.8391961Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mental Health Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/114", "label" : {"_value" : "Biography information for Tim Loughton"}
      }
      , "tablingMemberConstituency" : {"_value" : "East Worthing and Shoreham"}
      , "tablingMemberPrinted" : [{"_value" : "Tim Loughton"}
      ], "uin" : "210896"}
    , {"_about" : "http://data.parliament.uk/resources/100022", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100022/answer", "answerText" : {"_value" : "<p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.<\/p><p> <\/p><p> <\/p><p> <\/p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-21T16:00:56.1397924Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Patient Choice Schemes"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to promote patient choice.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4104", "label" : {"_value" : "Biography information for Neil Carmichael"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stroud"}
      , "tablingMemberPrinted" : [{"_value" : "Neil Carmichael"}
      ], "uin" : "905559"}
    , {"_about" : "http://data.parliament.uk/resources/92838", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/92838/answer", "answerText" : {"_value" : "<p>Under the current legislative framework, continence products are supplied by pharmaceutical services providers, including pharmacists, dispensing appliance contractors and dispensing doctors in response to a National Health Service prescription. Part IX of the Drug Tariff sets out the products that general practitioners can prescribe on an NHS prescription in primary care. If there are local arrangements outside of these national arrangements, it would be for local commissioners as part of their commissioning process to assess the suitability of these arrangements.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-21T16:30:30.3202909Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Incontinence: Products"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will make an assessment of the difficulties created by users of continence products by the practices from wholesalers and the introduction of off script supply and formularies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1604", "label" : {"_value" : "Biography information for Mr Virendra Sharma"}
      }
      , "tablingMemberConstituency" : {"_value" : "Ealing, Southall"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Virendra Sharma"}
      ], "uin" : "210134"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}